HR and breast cancer: As a result, regulatory authorities including the U.S. FDA and other global pharmaceutical agencies have granted licenses for the use of CDK4/6 inhibitors in combination with endocrine therapy or as standalone treatments (Abemaciclib) for the initial management of HR+/HER2– breast cancer patients (16).